Skip to main
GRI

GRI Stock Forecast & Price Target

GRI Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

GRI Bio is a clinical-stage biopharmaceutical company focused on developing therapies for dysregulated immune responses and has two promising product candidates, GRI-0621 and GRI-0803. With a current valuation that represents significant upside potential and a large market potential for IPF, GRI Bio Inc could see success in the future. Additionally, GRI Bio's financial results for the fiscal Q3 of 2025 show losses, but this is to be expected from a clinical-stage drug development company with no current revenue. The company has recently undergone multiple reverse stock splits, likely in an effort to boost its share price and attract investors.

Bears say

GRI Bio is currently experiencing a positive outlook with its recent top-line data release for GRI-0621 demonstrating positive results in its Phase 2a study for IPF. Along with this promising drug candidate, the company's second planned product, GRI-0803, also shows potential as a treatment for autoimmune disorders, a market with a large potential patient population. The company also has a strong balance sheet with enough cash to support its operations through mid-2027 and a current buy rating with an attractive 12-month price target, making it an interesting investment opportunity. However, there are potential risks associated with clinical trials and drug development, so careful consideration and monitoring of the company's progress is necessary.

GRI has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GRI Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GRI Bio Inc (GRI) Forecast

Analysts have given GRI a Strong Buy based on their latest research and market trends.

According to 2 analysts, GRI has a Strong Buy consensus rating as of May 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GRI Bio Inc (GRI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.